EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

The impact of interleukin-6 receptor inhibitors on risk of diabetes mellitus in patients with giant cell arteritis: a cohort study

Mads E R Sørensen, Sille Sophie Lindhardt Petersen, Anne Lund Overgaard, Maria Kristina Stilling-Vinther, Esther Gaarn Lindgreen, Lone Salomonsen, Wilfred Kjær Hanefelt Dinesen, Katja Bailum Knudsen, Kathrine Banke Hansen, Martin Jensen, Kirsten S Duch, Line Uhrenholt und 3 weitere

Rheumatology International · 26.06.2026 · 46 (7)

DOI: 10.1007/s00296-026-06189-y ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Rheumatology International, online erschienen am 26.06.2026. Verfasst von Mads E R Sørensen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark. m.engell@rn.dk. Hauptthemen laut MEDLINE: Giant Cell Arteritis, Diabetes Mellitus, Glucocorticoids, Receptors, Interleukin-6. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aalborg University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To investigate the one-year incidence of diabetes mellitus (DM) among patients with giant cell arteritis (GCA) treated with glucocorticoids and interleukin-6 receptor inhibitor (IL-6Ri) compared to patients treated with glucocorticoid monotherapy. Secondary we investigated the one-year risk of a composite outcome of DM, osteoporosis and cardiovascular events. This cohort study at Aalborg University Hospital, Denmark included patients with GCA from June 2022 to August 2025. Data was collected at diagnosis and at 4, 12, and 24 weeks after glucocorticoid initiation, and annually thereafter. We evaluated the one-year incidence of DM, and thereafter the risk the composite outcome using a Cox regression, comparing patients receiving glucocorticoids in combination with IL-6Ri (exposed) versus glucocorticoid monotherapy (unexposed). The study included 121 patients (70.2% female; mean age 70.5 years): 47 exposed and 74 unexposed. A median of 193 days passed from GCA diagnosis to IL-6Ri initiation in exposed. The one-year cumulative incidence of DM was 3.0% in exposed and 17.5% in unexposed. Exposed had a lower composite risk (Hazard ratio: 0.3, 95% confidence interval: 0.1;1.3). The most frequent AEs among exposed were infections, osteoporosis, cardiovascular events, and DM in exposed and unexposed. Both the one-year cumulative incidence of DM and the composite risk of adverse events were lower in exposed compared with unexposed. These findings suggest that IL-6Ri may offer a safer alternative to glucocorticoid monotherapy in reducing long-term risks. Additionally, the data indicate that IL-6Ri may be introduced too late in the disease course.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Giant Cell ArteritisDiabetes MellitusGlucocorticoidsReceptors, Interleukin-6HumansFemaleMaleAgedIncidenceAged, 80 and overMiddle AgedDenmarkRisk FactorsCohort StudiesDrug Therapy, Combination

Stichwörter der Autor:innen

Cardiovascular diseaseClinical trialCohort studyComorbiditiesDiabetes mellitusGiant cell arteritisGlucocorticoidsInterleukin-6 receptor inhibitorOsteoporosisTocilizumab

Substanzen

GlucocorticoidsReceptors, Interleukin-6

Autor:innen und Institutionen

  • Centre for Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark. m.engell@rn.dk.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. m.engell@rn.dk.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Centre for Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.
  • Research Data and Biostatistics, Aalborg University Hospital, Aalborg, Denmark.
  • Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University Copenhagen, Aalborg, Denmark.

Förderung

  • Aalborg University Hospital

Zitieren

APA

Sørensen, M. E. R., Lindhardt Petersen, S. S., Overgaard, A. L., Stilling-Vinther, M. K., Lindgreen, E. G., Salomonsen, L., Dinesen, W. K. H., Knudsen, K. B., Hansen, K. B., Jensen, M., Duch, K. S., Uhrenholt, L., Soussi, B. G., Dreyer, L. W., & Kristensen, S. (2026). The impact of interleukin-6 receptor inhibitors on risk of diabetes mellitus in patients with giant cell arteritis: a cohort study. Rheumatology International, 46(7). https://doi.org/10.1007/s00296-026-06189-y

Vancouver

Sørensen MER, Lindhardt Petersen SS, Overgaard AL, Stilling-Vinther MK, Lindgreen EG, Salomonsen L, et al. The impact of interleukin-6 receptor inhibitors on risk of diabetes mellitus in patients with giant cell arteritis: a cohort study. Rheumatology International. 2026;46(7). doi:10.1007/s00296-026-06189-y

BibTeX
@article{Srensen2026,
  author = {Sørensen, Mads E R and Lindhardt Petersen, Sille Sophie and Overgaard, Anne Lund and Stilling-Vinther, Maria Kristina and Lindgreen, Esther Gaarn and Salomonsen, Lone and Dinesen, Wilfred Kjær Hanefelt and Knudsen, Katja Bailum and Hansen, Kathrine Banke and Jensen, Martin and Duch, Kirsten S and Uhrenholt, Line and Soussi, Bolette Gylden and Dreyer, Lene Wohlfahrt and Kristensen, Salome},
  title = {The impact of interleukin-6 receptor inhibitors on risk of diabetes mellitus in patients with giant cell arteritis: a cohort study},
  journal = {Rheumatology International},
  year = {2026},
  volume = {46},
  number = {7},
  doi = {10.1007/s00296-026-06189-y}
}
Kostenlos starten →